

# Global Attenuated Vaccine for Human Rabies Market Growth 2022-2028

<https://marketpublishers.com/r/GC2CB24B627BEN.html>

Date: October 2022

Pages: 114

Price: US\$ 3,660.00 (Single User License)

ID: GC2CB24B627BEN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global market for Attenuated Vaccine for Human Rabies is estimated to increase from US\$ million in 2021 to reach US\$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Attenuated Vaccine for Human Rabies market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Attenuated Vaccine for Human Rabies market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Attenuated Vaccine for Human Rabies market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Attenuated Vaccine for Human Rabies market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Attenuated Vaccine for Human Rabies players cover AstraZeneca, GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc and Cadila Pharmaceuticals Ltd, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

## Report Coverage

This latest report provides a deep insight into the global Attenuated Vaccine for Human Rabies market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Attenuated Vaccine for Human Rabies market, with both quantitative and qualitative data, to help readers understand how the Attenuated Vaccine for Human Rabies market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

## Market Segmentation:

The study segments the Attenuated Vaccine for Human Rabies market and forecasts the market size by Type (Vero Cell and Human Diploid Cell), by Application (Hospital and Clinic.), and region (APAC, Americas, Europe, and Middle East & Africa).

### Segmentation by type

Vero Cell

Human Diploid Cell

### Segmentation by application

Hospital

Clinic

### Segmentation by region

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

#### Major companies covered

AstraZeneca

GlaxoSmithKline

Merck & Co Inc

Sanofi Pasteur, Inc

Cadila Pharmaceuticals Ltd

Novartis AG

Pfizer Inc

Liaoning Yisheng Biopharmaceutical Co., Ltd

Lanzhou Institute of Biological Products Co., Ltd

Changchun Zhuoyi Biological Co., Ltd

Guangzhou Nuocheng Biological Products Co., Ltd

Ningbo Rongan Biopharmaceutical Co., Ltd

Shandong Yidu Biotechnology Co., Ltd

Chengdu Kanghua Biological Products Co., Ltd

## Wuhan Institute of Biological Products Co., Ltd

### Chapter Introduction

Chapter 1: Scope of Attenuated Vaccine for Human Rabies, Research Methodology, etc.

Chapter 2: Executive Summary, global Attenuated Vaccine for Human Rabies market size (sales and revenue) and CAGR, Attenuated Vaccine for Human Rabies market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.

Chapter 3: Attenuated Vaccine for Human Rabies sales, revenue, average price, global market share, and industry ranking by company, 2017-2022

Chapter 4: Global Attenuated Vaccine for Human Rabies sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.

Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.

Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace

Chapter 10: Manufacturing cost structure analysis

Chapter 11: Sales channel, distributors, and customers

Chapter 12: Global Attenuated Vaccine for Human Rabies market size forecast by region, by country, by type, and application.

Chapter 13: Comprehensive company profiles of the leading players, including AstraZeneca, GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, Cadila Pharmaceuticals Ltd, Novartis AG, Pfizer Inc, Liaoning Yisheng Biopharmaceutical Co., Ltd and Lanzhou Institute of Biological Products Co., Ltd, etc.

## Chapter 14: Research Findings and Conclusion

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global Attenuated Vaccine for Human Rabies Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Attenuated Vaccine for Human Rabies by Geographic Region, 2017, 2022 & 2028
- 2.1.3 World Current & Future Analysis for Attenuated Vaccine for Human Rabies by Country/Region, 2017, 2022 & 2028

#### 2.2 Attenuated Vaccine for Human Rabies Segment by Type

- 2.2.1 Vero Cell
- 2.2.2 Human Diploid Cell

#### 2.3 Attenuated Vaccine for Human Rabies Sales by Type

- 2.3.1 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
- 2.3.2 Global Attenuated Vaccine for Human Rabies Revenue and Market Share by Type (2017-2022)
- 2.3.3 Global Attenuated Vaccine for Human Rabies Sale Price by Type (2017-2022)

#### 2.4 Attenuated Vaccine for Human Rabies Segment by Application

- 2.4.1 Hospital
- 2.4.2 Clinic

#### 2.5 Attenuated Vaccine for Human Rabies Sales by Application

- 2.5.1 Global Attenuated Vaccine for Human Rabies Sale Market Share by Application (2017-2022)
- 2.5.2 Global Attenuated Vaccine for Human Rabies Revenue and Market Share by Application (2017-2022)
- 2.5.3 Global Attenuated Vaccine for Human Rabies Sale Price by Application (2017-2022)

### **3 GLOBAL ATTENUATED VACCINE FOR HUMAN RABIES BY COMPANY**

#### 3.1 Global Attenuated Vaccine for Human Rabies Breakdown Data by Company

3.1.1 Global Attenuated Vaccine for Human Rabies Annual Sales by Company (2020-2022)

3.1.2 Global Attenuated Vaccine for Human Rabies Sales Market Share by Company (2020-2022)

3.2 Global Attenuated Vaccine for Human Rabies Annual Revenue by Company (2020-2022)

3.2.1 Global Attenuated Vaccine for Human Rabies Revenue by Company (2020-2022)

3.2.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company (2020-2022)

3.3 Global Attenuated Vaccine for Human Rabies Sale Price by Company

3.4 Key Manufacturers Attenuated Vaccine for Human Rabies Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Attenuated Vaccine for Human Rabies Product Location Distribution

3.4.2 Players Attenuated Vaccine for Human Rabies Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

### **4 WORLD HISTORIC REVIEW FOR ATTENUATED VACCINE FOR HUMAN RABIES BY GEOGRAPHIC REGION**

4.1 World Historic Attenuated Vaccine for Human Rabies Market Size by Geographic Region (2017-2022)

4.1.1 Global Attenuated Vaccine for Human Rabies Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Attenuated Vaccine for Human Rabies Annual Revenue by Geographic Region

4.2 World Historic Attenuated Vaccine for Human Rabies Market Size by Country/Region (2017-2022)

4.2.1 Global Attenuated Vaccine for Human Rabies Annual Sales by Country/Region (2017-2022)



- 4.2.2 Global Attenuated Vaccine for Human Rabies Annual Revenue by Country/Region
- 4.3 Americas Attenuated Vaccine for Human Rabies Sales Growth
- 4.4 APAC Attenuated Vaccine for Human Rabies Sales Growth
- 4.5 Europe Attenuated Vaccine for Human Rabies Sales Growth
- 4.6 Middle East & Africa Attenuated Vaccine for Human Rabies Sales Growth

## **5 AMERICAS**

- 5.1 Americas Attenuated Vaccine for Human Rabies Sales by Country
  - 5.1.1 Americas Attenuated Vaccine for Human Rabies Sales by Country (2017-2022)
  - 5.1.2 Americas Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022)
- 5.2 Americas Attenuated Vaccine for Human Rabies Sales by Type
- 5.3 Americas Attenuated Vaccine for Human Rabies Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

## **6 APAC**

- 6.1 APAC Attenuated Vaccine for Human Rabies Sales by Region
  - 6.1.1 APAC Attenuated Vaccine for Human Rabies Sales by Region (2017-2022)
  - 6.1.2 APAC Attenuated Vaccine for Human Rabies Revenue by Region (2017-2022)
- 6.2 APAC Attenuated Vaccine for Human Rabies Sales by Type
- 6.3 APAC Attenuated Vaccine for Human Rabies Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

## **7 EUROPE**

- 7.1 Europe Attenuated Vaccine for Human Rabies by Country
  - 7.1.1 Europe Attenuated Vaccine for Human Rabies Sales by Country (2017-2022)

- 7.1.2 Europe Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022)
- 7.2 Europe Attenuated Vaccine for Human Rabies Sales by Type
- 7.3 Europe Attenuated Vaccine for Human Rabies Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

## **8 MIDDLE EAST & AFRICA**

- 8.1 Middle East & Africa Attenuated Vaccine for Human Rabies by Country
  - 8.1.1 Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Country (2017-2022)
  - 8.1.2 Middle East & Africa Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022)
- 8.2 Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Type
- 8.3 Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Attenuated Vaccine for Human Rabies
- 10.3 Manufacturing Process Analysis of Attenuated Vaccine for Human Rabies
- 10.4 Industry Chain Structure of Attenuated Vaccine for Human Rabies

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

- 11.1 Sales Channel
  - 11.1.1 Direct Channels
  - 11.1.2 Indirect Channels
- 11.2 Attenuated Vaccine for Human Rabies Distributors
- 11.3 Attenuated Vaccine for Human Rabies Customer

## **12 WORLD FORECAST REVIEW FOR ATTENUATED VACCINE FOR HUMAN RABIES BY GEOGRAPHIC REGION**

- 12.1 Global Attenuated Vaccine for Human Rabies Market Size Forecast by Region
  - 12.1.1 Global Attenuated Vaccine for Human Rabies Forecast by Region (2023-2028)
  - 12.1.2 Global Attenuated Vaccine for Human Rabies Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Attenuated Vaccine for Human Rabies Forecast by Type
- 12.7 Global Attenuated Vaccine for Human Rabies Forecast by Application

## **13 KEY PLAYERS ANALYSIS**

- 13.1 AstraZeneca
  - 13.1.1 AstraZeneca Company Information
  - 13.1.2 AstraZeneca Attenuated Vaccine for Human Rabies Product Offered
  - 13.1.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.1.4 AstraZeneca Main Business Overview
  - 13.1.5 AstraZeneca Latest Developments
- 13.2 GlaxoSmithKline
  - 13.2.1 GlaxoSmithKline Company Information
  - 13.2.2 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Offered
  - 13.2.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.2.4 GlaxoSmithKline Main Business Overview
  - 13.2.5 GlaxoSmithKline Latest Developments
- 13.3 Merck & Co Inc
  - 13.3.1 Merck & Co Inc Company Information
  - 13.3.2 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Offered

13.3.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Merck & Co Inc Main Business Overview

13.3.5 Merck & Co Inc Latest Developments

13.4 Sanofi Pasteur, Inc

13.4.1 Sanofi Pasteur, Inc Company Information

13.4.2 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Offered

13.4.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Sanofi Pasteur, Inc Main Business Overview

13.4.5 Sanofi Pasteur, Inc Latest Developments

13.5 Cadila Pharmaceuticals Ltd

13.5.1 Cadila Pharmaceuticals Ltd Company Information

13.5.2 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Offered

13.5.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Cadila Pharmaceuticals Ltd Main Business Overview

13.5.5 Cadila Pharmaceuticals Ltd Latest Developments

13.6 Novartis AG

13.6.1 Novartis AG Company Information

13.6.2 Novartis AG Attenuated Vaccine for Human Rabies Product Offered

13.6.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Novartis AG Main Business Overview

13.6.5 Novartis AG Latest Developments

13.7 Pfizer Inc

13.7.1 Pfizer Inc Company Information

13.7.2 Pfizer Inc Attenuated Vaccine for Human Rabies Product Offered

13.7.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Pfizer Inc Main Business Overview

13.7.5 Pfizer Inc Latest Developments

13.8 Liaoning Yisheng Biopharmaceutical Co., Ltd

13.8.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information

13.8.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

13.8.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)

- 13.8.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Main Business Overview
- 13.8.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Latest Developments
- 13.9 Lanzhou Institute of Biological Products Co., Ltd
  - 13.9.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  - 13.9.2 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
  - 13.9.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.9.4 Lanzhou Institute of Biological Products Co., Ltd Main Business Overview
  - 13.9.5 Lanzhou Institute of Biological Products Co., Ltd Latest Developments
- 13.10 Changchun Zhuoyi Biological Co., Ltd
  - 13.10.1 Changchun Zhuoyi Biological Co., Ltd Company Information
  - 13.10.2 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
  - 13.10.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.10.4 Changchun Zhuoyi Biological Co., Ltd Main Business Overview
  - 13.10.5 Changchun Zhuoyi Biological Co., Ltd Latest Developments
- 13.11 Guangzhou Nuocheng Biological Products Co., Ltd
  - 13.11.1 Guangzhou Nuocheng Biological Products Co., Ltd Company Information
  - 13.11.2 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
  - 13.11.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.11.4 Guangzhou Nuocheng Biological Products Co., Ltd Main Business Overview
  - 13.11.5 Guangzhou Nuocheng Biological Products Co., Ltd Latest Developments
- 13.12 Ningbo Rongan Biopharmaceutical Co., Ltd
  - 13.12.1 Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
  - 13.12.2 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
  - 13.12.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.12.4 Ningbo Rongan Biopharmaceutical Co., Ltd Main Business Overview
  - 13.12.5 Ningbo Rongan Biopharmaceutical Co., Ltd Latest Developments
- 13.13 Shandong Yidu Biotechnology Co., Ltd
  - 13.13.1 Shandong Yidu Biotechnology Co., Ltd Company Information
  - 13.13.2 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
  - 13.13.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies

Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Shandong Yidu Biotechnology Co., Ltd Main Business Overview

13.13.5 Shandong Yidu Biotechnology Co., Ltd Latest Developments

13.14 Chengdu Kanghua Biological Products Co., Ltd

13.14.1 Chengdu Kanghua Biological Products Co., Ltd Company Information

13.14.2 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

13.14.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Chengdu Kanghua Biological Products Co., Ltd Main Business Overview

13.14.5 Chengdu Kanghua Biological Products Co., Ltd Latest Developments

13.15 Wuhan Institute of Biological Products Co., Ltd

13.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information

13.15.2 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

13.15.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 Wuhan Institute of Biological Products Co., Ltd Main Business Overview

13.15.5 Wuhan Institute of Biological Products Co., Ltd Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Attenuated Vaccine for Human Rabies Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)

Table 2. Attenuated Vaccine for Human Rabies Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)

Table 3. Major Players of Vero Cell

Table 4. Major Players of Human Diploid Cell

Table 5. Global Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)

Table 6. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)

Table 7. Global Attenuated Vaccine for Human Rabies Revenue by Type (2017-2022) & (\$ million)

Table 8. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2017-2022)

Table 9. Global Attenuated Vaccine for Human Rabies Sale Price by Type (2017-2022) & (US\$/Unit)

Table 10. Global Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)

Table 11. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)

Table 12. Global Attenuated Vaccine for Human Rabies Revenue by Application (2017-2022)

Table 13. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2017-2022)

Table 14. Global Attenuated Vaccine for Human Rabies Sale Price by Application (2017-2022) & (US\$/Unit)

Table 15. Global Attenuated Vaccine for Human Rabies Sales by Company (2020-2022) & (K Units)

Table 16. Global Attenuated Vaccine for Human Rabies Sales Market Share by Company (2020-2022)

Table 17. Global Attenuated Vaccine for Human Rabies Revenue by Company (2020-2022) (\$ Millions)

Table 18. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company (2020-2022)

Table 19. Global Attenuated Vaccine for Human Rabies Sale Price by Company



(2020-2022) & (US\$/Unit)

Table 20. Key Manufacturers Attenuated Vaccine for Human Rabies Producing Area Distribution and Sales Area

Table 21. Players Attenuated Vaccine for Human Rabies Products Offered

Table 22. Attenuated Vaccine for Human Rabies Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Attenuated Vaccine for Human Rabies Sales by Geographic Region (2017-2022) & (K Units)

Table 26. Global Attenuated Vaccine for Human Rabies Sales Market Share Geographic Region (2017-2022)

Table 27. Global Attenuated Vaccine for Human Rabies Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 28. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Geographic Region (2017-2022)

Table 29. Global Attenuated Vaccine for Human Rabies Sales by Country/Region (2017-2022) & (K Units)

Table 30. Global Attenuated Vaccine for Human Rabies Sales Market Share by Country/Region (2017-2022)

Table 31. Global Attenuated Vaccine for Human Rabies Revenue by Country/Region (2017-2022) & (\$ millions)

Table 32. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Country/Region (2017-2022)

Table 33. Americas Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)

Table 34. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)

Table 35. Americas Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & (\$ Millions)

Table 36. Americas Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)

Table 37. Americas Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)

Table 38. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)

Table 39. Americas Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)

Table 40. Americas Attenuated Vaccine for Human Rabies Sales Market Share by



Application (2017-2022)

Table 41. APAC Attenuated Vaccine for Human Rabies Sales by Region (2017-2022) & (K Units)

Table 42. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Region (2017-2022)

Table 43. APAC Attenuated Vaccine for Human Rabies Revenue by Region (2017-2022) & (\$ Millions)

Table 44. APAC Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2017-2022)

Table 45. APAC Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)

Table 46. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)

Table 47. APAC Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)

Table 48. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)

Table 49. Europe Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)

Table 50. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)

Table 51. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & (\$ Millions)

Table 52. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)

Table 53. Europe Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)

Table 54. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)

Table 55. Europe Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)

Table 56. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)

Table 57. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)

Table 58. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)

Table 59. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & (\$ Millions)

- Table 60. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
- Table 61. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
- Table 62. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
- Table 63. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
- Table 64. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
- Table 65. Key Market Drivers & Growth Opportunities of Attenuated Vaccine for Human Rabies
- Table 66. Key Market Challenges & Risks of Attenuated Vaccine for Human Rabies
- Table 67. Key Industry Trends of Attenuated Vaccine for Human Rabies
- Table 68. Attenuated Vaccine for Human Rabies Raw Material
- Table 69. Key Suppliers of Raw Materials
- Table 70. Attenuated Vaccine for Human Rabies Distributors List
- Table 71. Attenuated Vaccine for Human Rabies Customer List
- Table 72. Global Attenuated Vaccine for Human Rabies Sales Forecast by Region (2023-2028) & (K Units)
- Table 73. Global Attenuated Vaccine for Human Rabies Sales Market Forecast by Region
- Table 74. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Region (2023-2028) & (\$ millions)
- Table 75. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Region (2023-2028)
- Table 76. Americas Attenuated Vaccine for Human Rabies Sales Forecast by Country (2023-2028) & (K Units)
- Table 77. Americas Attenuated Vaccine for Human Rabies Revenue Forecast by Country (2023-2028) & (\$ millions)
- Table 78. APAC Attenuated Vaccine for Human Rabies Sales Forecast by Region (2023-2028) & (K Units)
- Table 79. APAC Attenuated Vaccine for Human Rabies Revenue Forecast by Region (2023-2028) & (\$ millions)
- Table 80. Europe Attenuated Vaccine for Human Rabies Sales Forecast by Country (2023-2028) & (K Units)
- Table 81. Europe Attenuated Vaccine for Human Rabies Revenue Forecast by Country (2023-2028) & (\$ millions)
- Table 82. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Forecast

by Country (2023-2028) & (K Units)

Table 83. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 84. Global Attenuated Vaccine for Human Rabies Sales Forecast by Type (2023-2028) & (K Units)

Table 85. Global Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Type (2023-2028)

Table 86. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 87. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Type (2023-2028)

Table 88. Global Attenuated Vaccine for Human Rabies Sales Forecast by Application (2023-2028) & (K Units)

Table 89. Global Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Application (2023-2028)

Table 90. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 91. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Application (2023-2028)

Table 92. AstraZeneca Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 93. AstraZeneca Attenuated Vaccine for Human Rabies Product Offered

Table 94. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 95. AstraZeneca Main Business

Table 96. AstraZeneca Latest Developments

Table 97. GlaxoSmithKline Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 98. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Offered

Table 99. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 100. GlaxoSmithKline Main Business

Table 101. GlaxoSmithKline Latest Developments

Table 102. Merck & Co Inc Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 103. Merck & Co Inc Attenuated Vaccine for Human Rabies Product Offered

Table 104. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 105. Merck & Co Inc Main Business

Table 106. Merck & Co Inc Latest Developments

Table 107. Sanofi Pasteur, Inc Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 108. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Offered

Table 109. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 110. Sanofi Pasteur, Inc Main Business

Table 111. Sanofi Pasteur, Inc Latest Developments

Table 112. Cadila Pharmaceuticals Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 113. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Offered

Table 114. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 115. Cadila Pharmaceuticals Ltd Main Business

Table 116. Cadila Pharmaceuticals Ltd Latest Developments

Table 117. Novartis AG Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 118. Novartis AG Attenuated Vaccine for Human Rabies Product Offered

Table 119. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 120. Novartis AG Main Business

Table 121. Novartis AG Latest Developments

Table 122. Pfizer Inc Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 123. Pfizer Inc Attenuated Vaccine for Human Rabies Product Offered

Table 124. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 125. Pfizer Inc Main Business

Table 126. Pfizer Inc Latest Developments

Table 127. Liaoning Yisheng Biopharmaceutical Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 128. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

Table 129. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 130. Liaoning Yisheng Biopharmaceutical Co., Ltd Main Business

Table 131. Liaoning Yisheng Biopharmaceutical Co., Ltd Latest Developments

Table 132. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 133. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

Table 134. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 135. Lanzhou Institute of Biological Products Co., Ltd Main Business

Table 136. Lanzhou Institute of Biological Products Co., Ltd Latest Developments

Table 137. Changchun Zhuoyi Biological Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 138. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

Table 139. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 140. Changchun Zhuoyi Biological Co., Ltd Main Business

Table 141. Changchun Zhuoyi Biological Co., Ltd Latest Developments

Table 142. Guangzhou Nuocheng Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 143. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

Table 144. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 145. Guangzhou Nuocheng Biological Products Co., Ltd Main Business

Table 146. Guangzhou Nuocheng Biological Products Co., Ltd Latest Developments

Table 147. Ningbo Rongan Biopharmaceutical Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 148. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

Table 149. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 150. Ningbo Rongan Biopharmaceutical Co., Ltd Main Business

Table 151. Ningbo Rongan Biopharmaceutical Co., Ltd Latest Developments

Table 152. Shandong Yidu Biotechnology Co., Ltd Basic Information, Attenuated



Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 153. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

Table 154. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 155. Shandong Yidu Biotechnology Co., Ltd Main Business

Table 156. Shandong Yidu Biotechnology Co., Ltd Latest Developments

Table 157. Chengdu Kanghua Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 158. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

Table 159. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 160. Chengdu Kanghua Biological Products Co., Ltd Main Business

Table 161. Chengdu Kanghua Biological Products Co., Ltd Latest Developments

Table 162. Wuhan Institute of Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors

Table 163. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered

Table 164. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 165. Wuhan Institute of Biological Products Co., Ltd Main Business

Table 166. Wuhan Institute of Biological Products Co., Ltd Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. Picture of Attenuated Vaccine for Human Rabies

Figure 2. Attenuated Vaccine for Human Rabies Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Attenuated Vaccine for Human Rabies Sales Growth Rate 2017-2028 (K Units)

Figure 7. Global Attenuated Vaccine for Human Rabies Revenue Growth Rate 2017-2028 (\$ Millions)

Figure 8. Attenuated Vaccine for Human Rabies Sales by Region (2021 & 2028) & (\$ millions)

Figure 9. Product Picture of Vero Cell

Figure 10. Product Picture of Human Diploid Cell

Figure 11. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type in 2021

Figure 12. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2017-2022)

Figure 13. Attenuated Vaccine for Human Rabies Consumed in Hospital

Figure 14. Global Attenuated Vaccine for Human Rabies Market: Hospital (2017-2022) & (K Units)

Figure 15. Attenuated Vaccine for Human Rabies Consumed in Clinic

Figure 16. Global Attenuated Vaccine for Human Rabies Market: Clinic (2017-2022) & (K Units)

Figure 17. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)

Figure 18. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application in 2021

Figure 19. Attenuated Vaccine for Human Rabies Revenue Market by Company in 2021 (\$ Million)

Figure 20. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company in 2021

Figure 21. Global Attenuated Vaccine for Human Rabies Sales Market Share by Geographic Region (2017-2022)

Figure 22. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Geographic Region in 2021

Figure 23. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2017-2022)

Figure 24. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Country/Region in 2021

Figure 25. Americas Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)

Figure 26. Americas Attenuated Vaccine for Human Rabies Revenue 2017-2022 (\$ Millions)

Figure 27. APAC Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)

Figure 28. APAC Attenuated Vaccine for Human Rabies Revenue 2017-2022 (\$ Millions)

Figure 29. Europe Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)

Figure 30. Europe Attenuated Vaccine for Human Rabies Revenue 2017-2022 (\$ Millions)

Figure 31. Middle East & Africa Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)

Figure 32. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue 2017-2022 (\$ Millions)

Figure 33. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Country in 2021

Figure 34. Americas Attenuated Vaccine for Human Rabies Revenue Market Share by Country in 2021

Figure 35. United States Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 36. Canada Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 37. Mexico Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 38. Brazil Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 39. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Region in 2021

Figure 40. APAC Attenuated Vaccine for Human Rabies Revenue Market Share by Regions in 2021

Figure 41. China Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 42. Japan Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 43. South Korea Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)



Figure 44. Southeast Asia Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 45. India Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 46. Australia Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 47. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country in 2021

Figure 48. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country in 2021

Figure 49. Germany Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 50. France Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 51. UK Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 52. Italy Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 53. Russia Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 54. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country in 2021

Figure 55. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country in 2021

Figure 56. Egypt Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 57. South Africa Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 58. Israel Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 59. Turkey Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 60. GCC Country Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 (\$ Millions)

Figure 61. Manufacturing Cost Structure Analysis of Attenuated Vaccine for Human Rabies in 2021

Figure 62. Manufacturing Process Analysis of Attenuated Vaccine for Human Rabies

Figure 63. Industry Chain Structure of Attenuated Vaccine for Human Rabies

Figure 64. Channels of Distribution

Figure 65. Distributors Profiles

## I would like to order

Product name: Global Attenuated Vaccine for Human Rabies Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/GC2CB24B627BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC2CB24B627BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970